Home › Research › Biomarkers
Neuroimaging and biomarker evidence of neurodegeneration in asthma
Melissa A Rosenkranz, Douglas C Dean, Barbara B Bendlin, Nizar N Jarjour, Stephane Esnault, Henrik Zetterberg, Amanda Heslegrave, Michael D Evans et al.. The Journal of allergy and clinical immunology, 2021-09-15
Topic: Air pollution and environmental exposures
Plain-language summary
Asthma participants had widespread and large-magnitude differences in several dMRI metrics, which were indicative of neuroinflammation and neurodegeneration, and which were robustly associated with GFAP and, to a lesser extent, NfL. The AD biomarker p-Tau181 was only minimally associated with neuroimaging outcomes. Further, asthma severity was associated with deleterious changes in neuroimaging outcomes, which in turn were associated with slower processing speed, a test of cognitive performance. Asthma, particularly when severe, is associated with characteristics of neuroinflammation and neurodegeneration, and may be a potential risk factor for neural injury and cognitive dysfunction. There is a need to determine how asthma may affect brain health and whether treatment directed toward characteristics of asthma associated with these risks can mitigate these effects.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Rosenkranz, M. A., Dean, D. C., Bendlin, B. B., Jarjour, N. N., Esnault, S., Zetterberg, H., et al. (2022). Neuroimaging and biomarker evidence of neurodegeneration in asthma. The Journal of allergy and clinical immunology. https://doi.org/10.1016/j.jaci.2021.09.010
Vancouver
Rosenkranz MA, Dean DC, Bendlin BB, Jarjour NN, Esnault S, Zetterberg H, et al. Neuroimaging and biomarker evidence of neurodegeneration in asthma. The Journal of allergy and clinical immunology. 2022. doi:10.1016/j.jaci.2021.09.010. PMID: 34536414.
BibTeX
@article{rosenkranz2022-34536414,
author = {Rosenkranz, Melissa A and Dean, Douglas C and Bendlin, Barbara B and Jarjour, Nizar N and Esnault, Stephane and Zetterberg, Henrik and Heslegrave, Amanda and Evans, Michael D and others},
title = {{Neuroimaging and biomarker evidence of neurodegeneration in asthma}},
journal = {The Journal of allergy and clinical immunology},
year = {2022},
doi = {10.1016/j.jaci.2021.09.010},
pmid = {34536414},
url = {https://doi.org/10.1016/j.jaci.2021.09.010}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Asthma participants had widespread and large-magnitude differences in several dMRI metrics, which were indicative of neuroinflammation and neurodegeneration, and which were robustly associated with GFAP and, to a lesser extent, NfL.
- The AD biomarker p-Tau181 was only minimally associated with neuroimaging outcomes.
- Further, asthma severity was associated with deleterious changes in neuroimaging outcomes, which in turn were associated with slower processing speed, a test of cognitive performance.
- Asthma, particularly when severe, is associated with characteristics of neuroinflammation and neurodegeneration, and may be a potential risk factor for neural injury and cognitive dysfunction.
- There is a need to determine how asthma may affect brain health and whether treatment directed toward characteristics of asthma associated with these risks can mitigate these effects.
New to this subject? Start with our plain-English guide: Blood tests & biomarkers →
Study details
- Participants111
- Evidence strengthLow
How this study scored 50/100
Published in a peer-reviewed journal. Scored zero for study design, effect reported and randomized / blinded because the record does not state it. We have no data on journal's citation record, times cited, citations per year, impact for its field and year, cited by studies here, still being cited, senior author's track record, institution's track record, multicenter collaboration and free to read, so those were left out: it earned 28 of the 56 points we could judge it on, which is 50 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (The Journal of allergy and clinical immunology) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 0 / 12 | No study design recorded — scores zero, not guessed (not stated in the record — scored 0) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 3 / 5 | 2022 — within 6 year(s) of the newest study here |
| Sample size | 2 / 4 | 111 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 0 / 2 | No randomization or blinding stated — scores zero (not stated in the record — scored 0) |
| Times cited | — / 7 | No citation count (not found in OpenAlex) — left out of this score |
| Citations per year | — / 5 | No citation count or no year — left out of this score |
| Impact for its field and year | — / 6 | No field-weighted citation impact (OpenAlex has none yet) — left out of this score |
| Cited by studies here | — / 6 | Not yet checked against this library's citation graph — left out of this score |
| Still being cited | — / 4 | No yearly citation counts — left out of this score |
| Senior author's track record | — / 4 | Senior author's record not available — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | — / 3 | Institutions not listed — left out of this score |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 34536414) |
| Free to read | — / 2 | Access not recorded — left out of this score |
| Points | 28 / 56 | Scored on 10 of 20 parts. We have no data for the rest, so they are left out: 28 of the 56 points we could judge it on is 50 out of 100. |
| Total | 50 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
Free copy unknown: no free-copy check has an answer for this record yet. That does not mean it is paywalled.
Related
Studies in the library that share something with this one. The line above each title says what.
Related studies in Biomarkers from nearby years
Also tagged “particulate”
237 studies in the library carry the topic tag “particulate”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 237 tagged studies.